Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naïve patients

Stefania Paolucci1, Loretta Fiorina1, Bianca Mariani1, Roberto Gulminetti2, Stefano Novati2, Giorgio Barbarini3, Raffaele Bruno3 and Fausto Baldanti1*

Abstract

Background: Direct-acting antiviral (DAA) agents target HCV proteins; some of these have already been approved for the treatment of HCV infection, while others are in development. However, selection of DAA-resistant viral variants may hamper treatment. The aim of this study was to illustrate potential natural DAA-resistance mutations in the HCV NS5A and NS5B regions of HCV genotypes 1a and 1b from DAA-naïve patients.

Methods: Direct sequencing of HCV NS5A and NS5B regions was performed in 32 patients infected with HCV genotype 1a and 30 patients infected with HCV genotype 1b; all subjects were naïve to DAAs.

Results: In genotype 1a strains, resistance mutations in NS5A (M28V, L31M and H58P) were observed in 4/32 (12.5%) patients, and resistance mutations in NS5B (V321I, M426L, Y448H, Y452H) were observed in 4/32 (12.5%) patients. In genotype 1b, resistance mutations in NS5A (L28V, L31M, Q54H, Y93H and I280V) were observed in 16/30 (53.3%) patients, while resistance mutations in NS5B (L159F, V321I, C316N, M426L, Y452H, R465G and V499A) were observed in 27/30 (90%) patients.

Conclusions: Mutations conferring DAA resistance were detected in NS5A and NS5B of HCV genotypes 1a and 1b from DAA-naïve patients. Although some mutations confer only a low level of resistance, the presence at baseline of mutated HCV variants should be taken into consideration in the context of DAA therapy.

Keywords: Hepatitis C virus, HCV baseline resistance, NS5A and NS5B genes, DAA inhibitors

Background

Hepatitis C virus (HCV) is classified into six genotypes (1–6) and more than 100 subtypes. The most common genotypes in Western countries are 1a and 1b [1]. Peginterferon/ribavirin (PegIFN/RBV) for the treatment of HCV infection is burdened by adverse reactions in at least 10% of patients [2]. Moreover, a sustained virological response is achieved in only 50% of patients infected with HCV genotype 1 [3]. PegIFN/RBV treatment failure is mainly attributed to its low efficacy against genotypes 1 and 4, but also, to some extent to its side effects [3,4]. Recently developed direct-acting antiviral agents (DAAs) are predicted to have a major impact both in combination with PegIFN/RBV, as well as in IFN-free regimens and telaprevir and boceprevir have now been approved as standard of care treatment [5]. Targets for DAA include HCV NS3 protease, NS5B polymerase and NS5A protein which are essential for virus replication. [6–12].

Nevertheless, the combination of a high HCV replication rate, the low fidelity of HCV polymerase and selective pressures by the immune system and drug treatment lead to the in vivo development of viral quasispecies with high sequence diversity among various genotypes and subtypes [13,14] with the potential accumulation of virus variants showing mutations with varying degrees of resistance to DAAs [11-13,15-22], even in the absence of pre-existing drug-exposure [17,23-26]. In particular, natural changes in HCV NS5A and NS5B amino acids (aa) associated with reduced drug susceptibility have been observed in treatment naïve patients [17,27,28].
The aim of this study was to illustrate potential DAA-resistant variants in HCV NS5A and NS5B from DAA-naïve patients infected with genotypes 1a or 1b HCV strains.

Materials and methods
HCV DAA-naïve patients referred to our hospital between 2011 and 2012 were included in this study. A comparable number of sequential patients infected with HCV genotypes 1a or 1b was considered in the analysis. From each patient, serum samples were prospectively collected following approval of the study by the Ethics Committee of the Fondazione IRCCS Policlinico San Matteo (protocol no. 20080009620) and after obtaining written informed consent. HCV genotypes were defined using the Versant HCV Genotype 2.0 Assay LiPA (Siemens Healthcare Diagnostic Inc., Tarrytown, NY USA). NS5A and NS5B sequencing was used to differentiate HCV genotypes 1a and 1b. Data were analyzed with the Blast program (http://blast.ncbi.nlm.nih.gov).

Viral RNA was extracted from serum samples using the automatic Easy Mag extractor (Biomerieux, Lyon, France), and full-length HCV NS5A and NS5B genes were amplified using Superscript III One-step enzyme with Platinum Taq (Invitrogen, Carlsbad, CA, USA) in a nested RT-PCR. Primers used in the RT-PCR and nested PCR, spanning NS5a aa 1 to 406 and NS5b aa 1 to 547, are shown in Table 1. The PCR products in the first PCR round were obtained by using the following conditions: 30’ at 45°C for the reverse transcription followed by 10’ at 94°C, and then 50 cycles at 94°C for 1’, 60°C for 1’ and 68°C for 2’, with an extension at 68°C for 10’ in all reactions. Three micro-liters from the first PCR reaction were used in the nested PCR with the following conditions: denaturation step at 94°C for 10’ and then 30 cycles at 94°C for 1’, 60°C for 1’ and 72°C for 2’, with an extension at 72°C for 10’ in the NS5A gene; and denaturation step at 94°C for 10’ and then 30 cycles at 94°C for 1’, 65°C for 1’ and 72°C for 2’, with an extension at 72°C for 10’ in the NS5B gene.

Direct sequencing of PCR products was performed using an automatic sequencer (ABI PRISM 3100 genetic analyzer DNA Sequencer, Applied Biosystems, Foster City, CA, USA) and the BigDye Terminator v1.1 Cycle Sequencing kit (Applied Biosystems, Foster City, CA, USA). Sequencing primers used to complete the NS5A and NS5B analyses are shown in Table 1.

Nucleotide sequences were assembled using the Sequencer 5.0 (Gene Codes Corp., Ann Arbor, MI) software.

Table 1 Amplification and sequencing primers for HCV NS5A and NS5B in genotypes 1a and 1b

| Gene   | Primer name | Primer sequence |
|--------|-------------|----------------|
| GT1a* NS5A | HCV-1a NS5A Fwd out | GACACTCTGGGACTGGATTGATGTYGA |
|        | HCV-1a NS5A Rew out | GTTCAGGGWRTARGACATYGGAGCA |
|        | HCV-1a NS5A Fwd inn | GATATGYGAGGTGTAGACAGCA |
|        | HCV-1a NS5A Rew inn | GAGCARACACCGACRTCTYC |
|        | HCV-1a NS5A Rew Seq | AAGGATCCCACTACACAC |
|        | HCV-1a NS5B Fwd out | GGAGCCKGGRGATCCRGATCTGAG |
|        | HCV-1a NS5B Fwd inn | GGATYCGCGTGCTGCTGACAG |
|        | HCV-1a NS5B Fwd Seq | TCAGAAACCAGCTGGYCTCATG |
|        | HCV-1a NS5B Fwd Seq | CCTATGATTCACCTGGAGAG |
|        | HCV-1a NS5B Fwd Seq | GATAYAAYGARGACTGTYCYAC |
|        | HCV-1a NS5B Fwd Seq | GACCARGACCCGGTCRCTGAGRT |
|        | HCV-1a NS5B Fwd Seq | GGGAYTGGATATGCAGGTC |
| GT1a* NS5B | HCV-1b NS5A Fwd out | GGGGAGGCTGGGCTGGATG |
|        | HCV-1b NS5A Rew out | GATATGYGAGGTGTAGACAGCA |
|        | HCV-1b NS5A Fwd inn | GAGCARACACCGACRTCTYC |
|        | HCV-1b NS5A Fwd Seq | TCAGAAACCAGCTGGYCTCATG |
|        | HCV-1b NS5A Fwd Seq | CCTATGATTCACCTGGAGAG |
|        | HCV-1b NS5A Fwd Seq | GATAYAAYGARGACTGTYCYAC |
|        | HCV-1b NS5A Fwd Seq | GACCARGACCCGGTCRCTGAGRT |
|        | HCV-1b NS5A Fwd Seq | GGGAYTGGATATGCAGGTC |
| GT1b§ NS5A | HCV-1b NS5A Rew inn | GGGGAGGCTGGGCTGGATG |
|        | HCV-1b NS5B Fwd Seq | GATATGYGAGGTGTAGACAGCA |
|        | HCV-1b NS5B Fwd out | GAGCARACACCGACRTCTYC |
|        | HCV-1b NS5B Fwd out | TCAGAAACCAGCTGGYCTCATG |
|        | HCV-1b NS5B Fwd out | CCTATGATTCACCTGGAGAG |
|        | HCV-1b NS5B Fwd out | GATAYAAYGARGACTGTYCYAC |
|        | HCV-1b NS5B Fwd out | GACCARGACCCGGTCRCTGAGRT |
|        | HCV-1b NS5B Fwd out | GGGAYTGGATATGCAGGTC |
| GT1b§ NS5B | HCV-1b NS5B Fwd out | GGGGAGGCTGGGCTGGATG |
|        | HCV-1b NS5B Fwd out | GATATGYGAGGTGTAGACAGCA |
|        | HCV-1b NS5B Fwd out | GAGCARACACCGACRTCTYC |
|        | HCV-1b NS5B Fwd out | TCAGAAACCAGCTGGYCTCATG |
|        | HCV-1b NS5B Fwd out | CCTATGATTCACCTGGAGAG |
|        | HCV-1b NS5B Fwd out | GATAYAAYGARGACTGTYCYAC |
|        | HCV-1b NS5B Fwd out | GACCARGACCCGGTCRCTGAGRT |
|        | HCV-1b NS5B Fwd out | GGGAYTGGATATGCAGGTC |

*Genotype 1a; §Genotype 1b.
program. Nucleotide sequences were aligned with reference sequences of different subtypes. GeneBank accession numbers for NS5A and NS5B reference sequences are AF009606 for HCV genotype 1a, and AY045702 for genotype 1b.

The sequences reported in this study have been submitted to the GenBank database under accession numbers KF667756 - KF667879.

Results

The clinical and virological characteristics of the patients considered in the study are provided in Table 2. Most patients (26/32, 81%) were naive to PegIFN and RBV, while none had ever been treated with HCV NS3, NS5A or NS5B inhibitors. Ten out of 62 (16.2%) patients were co-infected with HIV and under treatment with highly active antiretroviral therapy (HAART), while 52/62 (83.8) were HCV mono-infected (Table 2).

DAA resistance mutations were detected in both genotypes 1a and 1b strains from DAA naïve HCV patients (Table 3 and Table 4). Overall, the median frequency of single mutations was 4.75% (range 3.1% and 36.6%). In detail, in genotype 1a strains, mutations in the NS5A region associated with resistance to Daclatasvir, Ledipasvir and GSK805 were observed in 4/32 (12.5%) patients (Table 3); mutations in the NS5B region associated with resistance to PSI-352938, Filibuvir and Tegobuvir were observed in 4/32 (12.5%) patients (Table 2). In genotype 1b strains, mutations in the NS5A region associated with resistance to Daclatasvir, Samatasvir, Ledipasvir and GSK805 were observed in 16/30 (53.3%) patients (Table 3); mutations in the NS5B region associated with resistance to Sofosbuvir, Mericitabine, PSI-352938, Tegobuvir, HCV-796, Filibuvir, JTK-109 and Deleobuvir were observed in 27/30 (90%) patients (Table 4). Of note, the mutation V499A was constitutively present in NS5B of all genotype 1a strains and mutation Q30R was present in NS5A of all genotype 1b strains. Overall, HCV NS5A and NS5B resistance mutations in HCV mono-infected patients were found in 30/62 (48.3%) patients.

HCV NS5A and NS5B resistance mutations in HCV/HIV co-infected patients were found in 3/10 (30%) patients with no statistical difference vs mono-infected patients (p = 0.32). In detail, one patient had the M28V mutation in NS5A, one patient had Y448H in NS5B and one patient had H58P + Y452H in NS5A and NS5B, respectively.

Among the 30 patients infected with genotype 1b strains, two (6.6%) had a mixture of virus variants carrying multiple NS5A resistance mutations, while eight (26.6%) exhibited a mixture of strains with multiple NS5B resistance mutations. In detail, in NS5A of two patients carrying genotype 1b, the mixture Q54H + Y93H was observed. In NS5B of eight patients with genotype 1b, eight different mixtures were observed (L159F + V499A; L159F + C316N; L159F + C316N + V499A; L159F + C316N + M426L; C316N + M426L; C316N + V499A; V321I + V499A and C316N + R465G + V499A). In addition, combinations of multiple resistance variants in both the NS5A and NS5B genes of the same HCV strain, were observed in 1/32 (3.1%) patients with HCV genotype 1a and 8/30 (26.6%) patients with HCV genotype 1b. In particular, a patient with genotype 1a infection had the H58P mutation in NS5A and Y452H in NS5B, while in the eight patients carrying genotype 1b, 3 patients had Q54H in NS5A and C316N in NS5B, one patient had L31M in NS5A and C316N in NS5B, one patient had L31M in NS5A and Y452H in NS5B, one patient had Q54H + Y93H in NS5A and C316N + V499A in NS5B, one patient had Q54H in NS5A and L159F in NS5B and one patient had Q54H in NS5A and L159F + C316N in NS5B.

Notably, all aa variants detected in DAA-naïve patients were low-level resistance mutations except for the mutation Y448H found in the NS5B gene of 1/32 (3.1%) HCV

Table 2: Patient characteristics by HCV genotype

| Characteristics                        | HCV genotype (no. of patients) |
|----------------------------------------|---------------------------------|
|                                        | 1a (n = 32)                     | 1b (n = 30)                     |
| Gender                                 | 22 (68.7%)                      | 17 (56.6%)                     |
| Female                                 | 10 (31.2%)                      | 13 (43.3%)                     |
| Demographics                           |                                 |                                |
| Italian                                | 31 (96.8%)                      | 25 (83.3%)                     |
| Others                                 | 1 (3.1%)                        | 5 (16.6%)                      |
| No. of HIV-1/HCV co-infected patients receiving HAART | 8 (25%)                        | 2 (6.6%)                       |
| Median HCV viral load (UI/ml) in HCV mono-infected patients | 1,614,064 (range 6,743-7,985,320) | 991,975 (range 3,470-4,381,000) |
| Median HCV viral load (UI/ml) in HCV/HIV co-infected patients | 2,367,635 (range 46,801-7,985,320) | 473,597 (range 46,801-900,393) |
| No. of patients naïve to peg IFN/RBV   | 26 (81.2%)                      | 29 (96.6%)                     |

HIV, Human Immunodeficiency Virus; HCV, Hepatitis C Virus; HAART, Highly Active Anti-Retroviral Therapy; IFN, Interferon; RBV, Ribavirin.
Table 3 Amino acid mutations in the HCV NS5A protein in DAA-naive patients infected with HCV genotypes 1a (n = 32) or 1b (n = 30)

| DAAs   | NS5A mutations in DAA-naive patients | References |
|--------|--------------------------------------|------------|
|        | Genotype 1a | Fold change in EC50 | Genotype 1b | Fold change in EC50 | |
| Daclatasvir | M28V (1/32, 3.1%) | 1.3 | L28MV (1/30, 3.3%) | 2.0 | [15,17,19] |
|         | Q30E/H/R/K |                        | R30H |                        | |
| Daclatasvir | L31M (1/32, 3.1%) | 341 | L31M (2/30, 6.6%) | 3.6 | [15,17,19] |
| Ledipasvir | L31M (1/32, 3.1%) | 140 | L31M | 3.1 | [29] |
| GSK805  | L31M (1/32, 3.1%) | >150 | L31M | 3.6 | [30] |
| Samatasvir | L31M |                        | L31M (2/30, 6.6%) | 3.6 | [31] |
|         | P32L |                        | P32L |                        | |
| Daclatasvir | Q54H/L/N |                        | Q54H (8/30, 26.6%) | 1.0 | [19] |
| Daclatasvir | H58T (2/32, 6.2%) | 1.2 | N96T |                        | |
| Daclatasvir | N69T |                        | N69T |                        | |
| Daclatasvir | A92V |                        | A92V |                        | |
| Daclatasvir | Y93C/H/N |                        | Y93H (3/30, 10%) | 24 | [15,17,19] |
| Ledipasvir | Y93C/H/N |                        | Y93H (3/30, 10%) | 1319 | [29] |
| Samatasvir | Y93C/H/N |                        | Y93H (3/30, 10%) | 93 | [31] |
|         | V153M |                        | V153M |                        | |
|         | R157W |                        | R157W |                        | |
|         | V198A |                        | V198A |                        | |
|         | M202L |                        | M202L |                        | |
|         | P223S |                        | P223S |                        | |
|         | M265V |                        | M265V |                        | |
| GSK805  | I280V |                        | I280V (2/30, 6,6%) | <2.0 | [30] |
|         | V298A |                        | V298A |                        | |
|         | V362A |                        | V362A |                        | |
|         | S364P |                        | S364P |                        | |
|         | S368P |                        | S368P |                        | |

*Amino acid changes conferring resistance to NS5A inhibitors are reported in italics. The number and % of patients with mutated strains is reported in brackets.

GeneBank accession number of NS5A reference sequence for HCV genotype 1a is AF009606, and for genotype 1b, AY045702.

**Discussion**

In this study, 62 patients with genotype 1a or 1b HCV strains were evaluated to determine the frequency of HCV DAA-resistant variants in patients naïve to DAA treatment. The identification of baseline resistance mutations to anti-HCV inhibitors is crucial for defining new therapeutic approaches. Relevant natural aa polymorphisms were found in genotypes 1a and 1b. Some major resistance mutations and other mutations conferring low level resistance to NS5A HCV inhibitors (Daclatasvir, Ledipasvir, GSK805 and Samatasvir), as well as nucleosides (Sofosbuvir, Mericitabine, and PSI-352938) and non-nucleosides (Tegobuvir, Filibuvir, HCV-796, JTK-109 and Deleobuvir) were observed. Similarly, resistance mutations to NS5B HCV inhibitors were confirmed in DAA naïve patients with HCV genotypes 1a and 1b [11,12,17,19,25,29-32,35,36]. Among major mutations in the NS5A gene conferring high level resistance to NS5A inhibitors [17,19,30,31], Q30E/H/K and Y93N/C were not observed, while L31M and Y93H were detected in 2 and 3 patients respectively. A major mutation in the NS5B gene S282T which confers high level resistance to polymerase nucleotide inhibitors [8,17,37], was not observed, while Y448H associated with reduced susceptibility to NS5B non-nucleoside polymerase inhibitors was detected in one patient. Resistance mutations were not observed more frequently in HCV/HIV co-infected patients than in HCV mono-infected patients.

Overall, the median frequency of single mutations observed in the NS5A and NS5B genes analyzed was low as reported in other geographical regions [17,27,28]. In
addition, the prevalence of patients with resistance mutations in both genes at baseline was lower in HCV genotype 1a than in HCV genotype 1b infected patients. The higher prevalence of mutations in genotype 1b is due to the presence of C316N, which confers low level resistance to Tegobuvir and HCV-796 in most genotype 1b strains. In addition, in HCV genotype 1b infected patients, the frequency of multiple variant combinations was lower in NS5A than in NS5B. Moreover, in HCV genotype 1a infected patients, combinations of multiple resistance mutations in both NS5A and NS5B of single patients were observed with significant frequency in both HCV genotype 1a and 1b infected patients. It should be underlined that while the Q54H + Y93H combination has already been reported [19] to provide moderate resistance to Daclatasvir, the other combinations have never been investigated, and their level of resistance is not known. In general, greater heterogeneity was confirmed in HCV genotype 1b strains [26,27].

Only 3.1% of patients with HCV genotype 1a and 10% with HCV genotype 1b had viral strains with mutations conferring higher-level resistance to Tegobuvir, Daclatasvir, Samatasvir Ledipasvir and GSK805. Although the presence of preexisting single or double mutations might not confer a significant level of resistance or preclude successful treatment as observed in PI treatment, the prevalence of patients with resistance mutations in both genes at baseline was lower in HCV genotype 1a than in HCV genotype 1b infected patients. The higher prevalence of mutations in genotype 1b is due to the presence of C316N, which confers low level resistance to Tegobuvir and HCV-796 in most genotype 1b strains. In addition, in HCV genotype 1b infected patients, the frequency of multiple variant combinations was lower in NS5A than in NS5B. Moreover, in HCV genotype 1a infected patients, combinations of multiple resistance mutations in both NS5A and NS5B of single patients were observed with significant frequency in both HCV genotype 1a and 1b infected patients. It should be underlined that while the Q54H + Y93H combination has already been reported [19] to provide moderate resistance to Daclatasvir, the other combinations have never been investigated, and their level of resistance is not known. In general, greater heterogeneity was confirmed in HCV genotype 1b strains [26,27].

Table 4 Amino acid mutations in the HCV NS5B protein in DAA-naïve patients infected with HCV genotypes 1a (n = 32) or 1b (n = 30)

| NS5B mutations in DAA-naïve patients | Genotype 1a | Fold change in EC50 | Genotype 1b | Fold change in EC50 | References |
|---------------------------------------|-------------|---------------------|-------------|---------------------|------------|
| DAAs                                  |             |                     |             |                     |            |
| Sofosbuvir + Mericitabine             |             |                     |             |                     |            |
| S96T                                  |             |                     | S96T        |                     |            |
| N142T                                 |             |                     | N142T       |                     |            |
| L159F                                 |             |                     | L159F (7/30, 23.3%) |            | X          |
| C223H/Y                               |             |                     | C223H/Y     |                     |            |
| S282T                                 |             |                     | S282T       |                     |            |
| L320F                                 |             |                     | L320F       |                     |            |
| PSI-352938                            |             | 2.0                 | V321I (1/30, 3.3%) |            |            |
| Tegobuvir + HCV796                    |             |                     |             |                     |            |
| C316Y/N/F/S                           |             |                     | C316N (1/30, 36.6%) |            | 3.0-5.2    |
| V362A                                 |             |                     | V362A       |                     |            |
| S365A/T                               |             |                     | S365A/T     |                     |            |
| M414T                                 |             |                     | M414T       |                     |            |
| L419W/S                               |             |                     | L419W/S     |                     |            |
| A421V                                 |             |                     | A421V       |                     |            |
| R422K                                 |             |                     | R422K       |                     |            |
| M423I/V/T                             |             |                     | M423I/V/T   |                     |            |
| Filibuvir                             |             | 0.8                 | M426L (2/30, 6.6%) |            | 0.8        |
| C445F                                 |             |                     | C445F       |                     |            |
| Tegobuvir                             |             | 36.0                | Y448H       |                     |            |
| Y448H                                 |             |                     |             |                     |            |
| Tegobuvir                             |             | 6.9                 | Y452H (1/30, 3.3%) |            | 6.9        |
| Tegobuvir                             |             |                     |             |                     |            |
| R465G                                 |             |                     | R465G (1/30, 3.3%) |            | 1.1        |
| I482L/T                               |             |                     | I482L/T     |                     |            |
| A486V                                 |             |                     | A486V       |                     |            |
| V494A                                 |             |                     | V494A       |                     |            |
| P495A/L/S/T                           |             |                     | P495A/L/S/T |                     |            |
| P496A/S                               |             |                     | P496A/S     |                     |            |
| JTK-109 + Deleobuvir                  |             |                     |             |                     |            |
| A499T                                 |             |                     | V499A (4/30, 13.3%) |            | 3.0        |
| G554D                                 |             |                     | G554D       |                     |            |
| S556G/D/N                             |             |                     | S556G/D/N   |                     |            |
| D559G/N                               |             |                     | D559G/N     |                     |            |

Amino acid changes conferring resistance to NS5B inhibitors are reported in italics. The number and % of patients with mutated strains is reported in brackets. Resistance levels are reported only when associated with L320F. GeneBank NS5B reference sequence accession number for HCV genotype 1a is AF009606, and for genotype 1b, AY045702.
baseline resistance should be taken into consideration in the prospect of HCV IFN-free DAA therapy. Of particular interest are patients carrying combinations of multiple resistance mutations in both the NS5A and NS5B genes, which might increase the possibility of failure in patients treated with multiple DAA containing regimens.

Further studies are needed to better evaluate the role of all variants and the influence which they might have in modulating resistance levels or susceptibility to HCV drugs.

The sustained response in most patients, even when carrying DAA baseline resistance, is probably due to the clearance of HCV. Although there is the possibility that baseline resistant variants may result in viral breakthroughs during treatment [20,27,29], the clinical impact of resistance-mutations in DAA-naïve patients and their influence on the ability of the virus to replicate in vivo remain unclear [14,17,25]. Thus, for patients receiving DAA interferon free regimens, or those who will receive in the near future only combined classes of HCV inhibitors, the potential role of DAA-resistant variants prior to treatment should be evaluated in all target genes since their clinical relevance could be useful in the management of new HCV therapies.

Consent
Written informed consent was obtained from patients for publication of the data in this manuscript and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Competing interests
The authors declare that they have no financial or competing interests.

Authors’ contributions
SP, LF, BM carried out the molecular analysis. RG, SN, GB, RB participated in the study design. SP interpreted the data and wrote the paper. All authors read and approved the final manuscript.

Acknowledgements
The authors thank Daniela Bartoli for manuscript editing and Laurene Kelly for revision of the English. The work was supported by the Ministero della Salute, Ricerca Corrente grant no. 80207.

References
1. Nakano T, Lau GM, Lau GM, Sugiyama M, Mizokami M: An updated analysis of hepatitis C virus genotypes and subtypes based on the complete coding region. Liver Int 2012, 32:339–345.
2. Manns MP, McHutchinson JG, Gordon SC, Rustgi VK, Schiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958–965.
3. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H Jr, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Avillam JL, PEGASYS International Study Group. Peginterferon-alfa2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004, 140:346–355.
4. Kowdley KV. Hematologic side effects of interferon and ribavirin therapy. J Clin Gastroenterol 2005, 39:1 Suppl:S5–S8.
5. Hunt D, Pockros P. What are the promising new therapies in the field of chronic hepatitis C after the first-generation direct-acting antivirals? Curr Hepatology 2013, 15:203.
6. Lenz O, Verbinnen C, Lin T, Viljen L, Cummings MD, Lindberg J, Berke JM, Dehertoghe P, Fransen E, Schollers A, Vermeiren K, Ivens T, Rappoport P, Edlund M, Storm S, Vang L, de Kock H, Fanning GC, Simmen KA. In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435. Antimicrob Agents Chemother 2010, 54:1878–1887.
7. Lagacé L, White PW, Bouquet C, Danreeau N, DS F, Llinares-Brunet M, Marquis M, Massaroli MJ, Maurice R, Spickler C, Thibault O, Trk I, Zhao S, Kukol G. In vitro resistance profile of the hepatitis C virus NS3 protease inhibitor BI 210335. Antimicrob Agents Chemother 2012, 56:569–572.
8. Membreno FE, Lawitz EJ. The HCV NS5B nucleoside and non-nucleoside inhibitors. Clin Liver Dis 2011, 15:611–626.
9. Chee GM, Poordad F. Interferon free hepatitis C treatment regimens: the beginning of another era. Curr Gastroenterol Rep 2012, 14:24–77.
10. Hagan JM, Schinazi RF: Best strategies for global HCV eradication. Liver Int 2013, 33(Suppl 1):68–79.
11. Pawlotsky JM. NSSA inhibitors in the treatment of hepatitis C. J Hepatol 2013, 59:375–382.
12. Alves R, Queiroz AT, Pessoa MG, da Silva EF, Mazo DF, Carlinho FI, Carvalho Filho R, de Carvalho W. The presence of resistance mutations to protease and polymerase inhibitors in Hepatitis C Virus sequences from the Los Alamos databank. J Viral Hepat 2013, 20:414–421.
13. Zeuzem S. Clinical implications of hepatitis C viral kinetics. Hepatol 1999, 31(1):61–64.
14. Palansiamy N, Danielsson A, Kokkala C, Yin H, Bondeson K, Wesslen L, Duberg AS. Lernerstrand J: Implications of basal polymorphisms for potential resistance to NS3 protease inhibitors in Hepatitis C virus genotypes 1a, 2b and 3a. Antiviral Res 2013, 99:12–17.
15. Fridell RA, Qiu D, Wang C, Valera L, Gao M. Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob Agents Chemother 2013, 57:3461–3460.
16. Adiwijaya BS, Hermann E, Hare B, Kieffer T, Lin C, Kwong AD, Garg V, Randle J, Sarzani C, Zeuzem S, Caron PR: A multi-variant, viral dynamic model of genotype 1 HCV to assess the in vivo evolution of protease-inhibitor resistant variants. PLoS Comput Biol 2010, 6(4):e1000745.
17. Bartels DJ, Sullivan JC, Zhang EZ, Tigges AM, Dorrian JL, De Meyer S, Takemoto D, Dondero E, Kwong AD, Pichco G, Kieffer TL: Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naïve patients prior to treatment. J Viral Hepat 2013, 20:1544–1553.
18. Delang L, Wiegens L, Leysen P, Neye J. In vitro selection and characterization of DAA replicons resistant to multiple non-nucleoside polymerase inhibitors. J Hepatol 2012, 56:41–48.
19. Fridell RA, Wang C, Sun JH, O’Boyle DR 2nd, Nowier P, Valera L, Qiu D, Roberts S, Huang X, Kienzle B, Bifano M, Netlles RE, Gao M: Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations. Hepatology 2011, 54:1924–1935.
20. Pelosi LA, Voss S, Liu M, Gao M, Lemm JA: Effect on hepatitis C virus replication of combinations of direct-acting antivirals, including NS5A inhibitor daclatasvir. Antimicrob Agents Chemother 2012, 56:5230–5239.
21. Troke PJ, Lewis M, Simpson P, Gore K, Hammond J, Craig C, Westby M. Characterization of resistance to the nonnucleoside NS5B inhibitor filibuvir in hepatitis C virus-infected patients. Antimicrob Agents Chemother 2012, 56:1331–1341.
22. Barreiro P, Vipso E, Poveda E, Fernandez-Montero JV, Soriano V: Hepatitis C therapy: highlights from the 2012 annual meeting of the European Association for the Study of the Liver. Clin Infect Dis 2013, 56:560–566.
23. Bartels DJ, Zhou Y, Zhang EZ, Marcial M, Byun RA, Pfeiffer T, Tegges AM, Adiwijaya BS, Lin C, Kwong AD, Kieffer TL: Natural prevalence of hepatitis...
C virus variants with decreased sensitivity to NS3/4A protease inhibitors in treatment-naive subjects. J Infect Dis 2008, 198:800–807.

24. Kuntzen T, Timm J, Berical A, Lennon N, Berlin AM, Young SK, Lee B, Heckerman D, Carlson J, Reytor LL, Kleyman M, McMahon CM, Birch C, Schulze Zur Wiesch J, Ledlie T, Koehnens M, Kodria C, Roberts AD, Lauer GM, Rosen HR, Biil F, Cemmy A, Spengler UJ, Liu Z, Kim AY, Xing Y, Schneidewind A, Madye MA, Fleckenstein JF, Park WM, et al. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients. Hepatology 2008, 48:1769–1778.

25. Halfon P, Sarrazin C. Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important? Liver Int 2012, 32(Suppl 1):97–87.

26. Paolucci S, Fiorina L, Pirala A, Guimrinni R, Novati S, Barbarini G, Sacchi P, Gatti M, Dossena I, Baidanti F. Naturally occurring mutations to HCV protease inhibitors in treatment-naive patients. Virol J 2012, 9:249–245.

27. Suzuki F, Szekzi H, Akuta N, Suzuki Y, Seko Y, Kawamura Y, Hosaka T, Kobayashi M, Saito S, Arase Y, Ikeda K, Kobayashi M, Mineta R, Watahiki S, Miyakawa Y, Kumada H. Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NSSA inhibitor (BMS-790053) in hepatitis patients with genotype 1b. J Clin Virol 2012, 54:352–354.

28. Plaza Z, Soriano V, Vispo E, del Mar Gonzalez M, Barreiro P, Sekelj E, Poveda E. Prevalence of natural polymorphisms at the HCV NSSA gene associated with resistance to daclatasvir, an NSSA inhibitor. Antivir Ther 2012, 17:921–926.

29. Lawitz EJ, Gruener D, Hill JM, Marbury T, Moorehead L, Mathias A, Cheng G, Link JO, Wong KA, Mo H, Mchutchison JG, Brainard DN. A phase 3, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NSSA inhibitor, in patients with genotype 1 hepatitis C. J Hepatol 2012, 57:24–31.

30. Walker J, Crosby R, Wang A, Woldu E, Vamathevan J, Voitenleitner C, You S, Remlingker K, Duan M, Kazmierski W, Hamatate R. Preclinical characterization of GS2336805, a novel inhibitor of hepatitis C virus replication that selects for resistance in NS5A. Antimicrob Agents Chemother 2013 [Epub ahead of print].

31. McCarville JF, Chapron C, LaColla M, Bilello JP, Lallos LB, Seifer M, Standring DN. Hepatitis C Virus NSSA Inhibitor IDX719 Demonstrates Potent, Pan-genotypic Activity in Preclinical and Clinical Studies [abstract]. Hepatol Int 2013, 7:5330.

32. Tong X, Le Pogam S, Li L, Haines K, Piso K, Baranovs V, Yan JM, So SS, Klumpp K, Najera I. In Vivo Emergence of a Novel Mutant L159F/L320F in the NS5B Polymerase Confers Low-Level Resistance to the HCV Polymerase Inhibitors Mericitabine and Sofosbuvir. J Infect Dis 2013 [Epub ahead of print].

33. Lam AM, Espiritu C, Bansal S, Micolochick Steuer HM, Zennou V, Otto MJ. Naturally occurring dominant resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naive patients. Virollogy Journal 2013 10:355.